Assessing the Induction of Long-term Immune Regulation Following Treatment With Lemtrada (Alemtuzumab)
Phase of Trial: Phase IV
Latest Information Update: 04 Mar 2019
Price : $35 *
At a glance
- Drugs Alemtuzumab (Primary)
- Indications Multiple sclerosis
- Focus Therapeutic Use
- 27 Feb 2019 Status changed from not yet recruiting to recruiting.
- 09 Oct 2018 Planned initiation date changed from 1 Sep 2018 to 31 Oct 2018.
- 04 Sep 2018 New trial record